Overview
Polyvascular Patients: Are You Doing Enough to Reduce Risk of Recurrent Events?
Click on this button to view this activity
Learn More
Cardiology expert, Christian Ruff, MD, MPH & primary care specialist, Elaine Hylek, MD, MPH review the latest research and recommendations for patients with polyvascular disease. The faculty also discuss patient cases that cover long-term atherothrombotic risks, chronic coronary artery disease (CAD)/peripheral artery disease (PAD), benefits of direct oral anticoagulants (DOACs), and considerations for the multidisciplinary team.
Supported by an educational grant from Janssen Scientific Affairs, LLC.
Updated on August 24, 2021: Based on data from the VOYAGER PAD trial, the FDA approved an expanded peripheral artery disease (PAD) indication for the rivaroxaban vascular dose (2.5 mg twice daily + aspirin 100 mg once daily) for use in patients who recently underwent lower-extremity revascularization due to symptomatic PAD.
Elaine Hylek, MD, MPH
Professor of Medicine Boston University School of Medicine
Christian Ruff, MD, MPH
Director, General Cardiology, Cardiovascular Division Brigham and Women's Hospital Associate Professor Harvard Medical School Senior Investigator, TIMI Group
Professor of Medicine Boston University School of Medicine
Christian Ruff, MD, MPH
Director, General Cardiology, Cardiovascular Division Brigham and Women's Hospital Associate Professor Harvard Medical School Senior Investigator, TIMI Group
